MP07-66 NEW
| Price | $59 | $95 | $172 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-06 |
Product Details
| Product Name: MP07-66 | CAS No.: 1938056-90-6 |
| Purity: 97.83% | Supply Ability: 10g |
| Release date: 2026/06/06 |
Product Introduction
Bioactivity
| Name | MP07-66 |
| Description | MP07-66 is a novel FTY720-analog devoid of immunosuppressive effects leads to the reactivation of PP2A, which in turn triggers apoptosis of CLL cells. |
| In vitro | CLL cells were incubated with increasing concentrations of MP07-66 (0-16 μM) for 24 and 48 hours and then subject to annexin V–PI flow cytometry. The level of apoptosis reached 50% and 80%, at 24 hours and 48 hours, respectively, at a MP07-66 concentration as high as 16 μM, which paralleled PARP cleavage, a marker of caspase-dependent apoptosis. In addition, the phosphorylation status of PP2A targets, namely Akt, GSK-3, and SHP-1, was negatively affected by the treatment with MP07-66, triggering known downstream events promoting apoptosis, such as Mcl-1 degradation and caspase-3 activation[1]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (772.87 mM), Sonication is recommended. |
| Keywords | SET-PP2A complex | SET-PP2A | Phosphatase | MP07-66 | MP-07-66 | MP0766 | MP07 66 | Inhibitor | inhibit | immunosuppressive effects | FTY720 analogue | chronic lymphocytic leukemia | antitumor effects |
| Inhibitors Related | β-Glycerophosphate disodium salt pentahydrate | Hexane-1,6-diol | 2-[dodecyl(2-hydroxyethyl)amino]ethanol | Idoxuridine | Cyclosporine | Tartaric acid disodium dihydrate | Stearic acid | CaMKP Inhibitor | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | L-Ascorbic acid 2-phosphate | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Apoptosis Compound Library | Glycometabolism Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Phosphatase Inhibitor Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2026-03-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY